- Home
- VANI vs EQH Comparison
VANI vs EQH Comparison
Compare VANI & EQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- EQH
- Stock Information
- Founded
- VANI 1998
- EQH 1859
- Country
- VANI United States
- EQH United States
- Employees
- VANI N/A
- EQH N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- EQH Specialty Insurers
- Sector
- VANI Health Care
- EQH Finance
- Exchange
- VANI Nasdaq
- EQH Nasdaq
- Market Cap
- VANI 75.2M
- EQH N/A
- IPO Year
- VANI 2014
- EQH N/A
- Fundamental
- Price
- VANI $1.50
- EQH $53.37
- Analyst Decision
- VANI Strong Buy
- EQH Strong Buy
- Analyst Count
- VANI 1
- EQH 10
- Target Price
- VANI $4.00
- EQH $65.30
- AVG Volume (30 Days)
- VANI 141.6K
- EQH 2.7M
- Earning Date
- VANI 08-12-2025
- EQH 08-05-2025
- Dividend Yield
- VANI N/A
- EQH 2.05%
- EPS Growth
- VANI N/A
- EQH 13.70
- EPS
- VANI N/A
- EQH 3.76
- Revenue
- VANI N/A
- EQH $15,105,000,000.00
- Revenue This Year
- VANI N/A
- EQH $19.33
- Revenue Next Year
- VANI N/A
- EQH $0.28
- P/E Ratio
- VANI N/A
- EQH $14.05
- Revenue Growth
- VANI N/A
- EQH 45.39
- 52 Week Low
- VANI $0.91
- EQH $36.46
- 52 Week High
- VANI $1.50
- EQH $56.61
- Technical
- Relative Strength Index (RSI)
- VANI 74.26
- EQH 48.28
- Support Level
- VANI $1.26
- EQH $54.39
- Resistance Level
- VANI $1.30
- EQH $56.42
- Average True Range (ATR)
- VANI 0.06
- EQH 1.16
- MACD
- VANI 0.00
- EQH -0.22
- Stochastic Oscillator
- VANI 69.70
- EQH 32.74
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.